Sabra Healthcare REIT Inc (NASDAQ: SBRA) has a higher price-to-earnings ratio of 32.69x compared to its average ratio, The 36-month beta value for SBRA is at 0.85. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for SBRA is 233.61M, and currently, shorts hold a 8.17% of that float. The average trading volume for SBRA on April 30, 2025 was 2.50M shares.
SBRA) stock’s latest price update
The stock price of Sabra Healthcare REIT Inc (NASDAQ: SBRA) has surged by 0.06 when compared to previous closing price of 17.50, but the company has seen a -2.29% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-28 that Sabra Health Care REIT’s strong fundamentals, 6.62% dividend yield, and low forward multiple make it an attractive investment amid tariff uncertainties and potential recession. The REIT’s solid growth in FFO, AFFO, and revenue, driven by increased occupancy rates and NOI growth, highlights its resilience in a challenging economic environment. Sabra’s well-positioned balance sheet, with robust liquidity and deleveraging efforts, ensures stability and growth potential, even during economic downturns.
SBRA’s Market Performance
SBRA’s stock has fallen by -2.29% in the past week, with a monthly drop of -0.17% and a quarterly rise of 3.00%. The volatility ratio for the week is 1.80% while the volatility levels for the last 30 days are 3.09% for Sabra Healthcare REIT Inc The simple moving average for the past 20 days is 0.23% for SBRA’s stock, with a 0.59% simple moving average for the past 200 days.
Analysts’ Opinion of SBRA
JMP Securities, on the other hand, stated in their research note that they expect to see SBRA reach a price target of $20. The rating they have provided for SBRA stocks is “Mkt Outperform” according to the report published on January 07th, 2025.
Mizuho gave a rating of “Neutral” to SBRA, setting the target price at $20 in the report published on December 05th of the previous year.
SBRA Trading at 2.16% from the 50-Day Moving Average
After a stumble in the market that brought SBRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.41% of loss for the given period.
Volatility was left at 3.09%, however, over the last 30 days, the volatility rate increased by 1.80%, as shares surge +0.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.99% upper at present.
During the last 5 trading sessions, SBRA fell by -2.29%, which changed the moving average for the period of 200-days by +11.96% in comparison to the 20-day moving average, which settled at $17.47. In addition, Sabra Healthcare REIT Inc saw 1.10% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SBRA starting from Cusack Catherine, who purchase 1,500 shares at the price of $15.92 back on Feb 24 ’25. After this action, Cusack Catherine now owns 60,583 shares of Sabra Healthcare REIT Inc, valued at $23,880 using the latest closing price.
Cusack Catherine, the Director of Sabra Healthcare REIT Inc, purchase 1,000 shares at $16.43 during a trade that took place back on Feb 21 ’25, which means that Cusack Catherine is holding 59,083 shares at $16,435 based on the most recent closing price.
Stock Fundamentals for SBRA
Current profitability levels for the company are sitting at:
- 0.37 for the present operating margin
- 0.58 for the gross margin
The net margin for Sabra Healthcare REIT Inc stands at 0.18. The total capital return value is set at 0.07. Equity return is now at value 4.57, with 2.37 for asset returns.
Based on Sabra Healthcare REIT Inc (SBRA), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.18. The debt to equity ratio resting at 0.64. The interest coverage ratio of the stock is 2.27.
Currently, EBITDA for the company is 412.61 million with net debt to EBITDA at 3.97. When we switch over and look at the enterprise to sales, we see a ratio of 8.25. The receivables turnover for the company is 1.39for trailing twelve months and the total asset turnover is 0.13.
Conclusion
In conclusion, Sabra Healthcare REIT Inc (SBRA) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
